Skip to main content
. 2017 May;187(5):940–953. doi: 10.1016/j.ajpath.2017.01.010

Figure 2.

Figure 2

A series of T1-weighted images after contrast depict the clinical course of a 41-year-old man with a large recurrence of glioblastoma in the right cerebral hemisphere who received 17 administrations of bevacizumab (BEV) over 36 months. A: Baseline imaging before starting BEV shows heterogenous areas of enhancement. B–D: Six (B), 30 (C), and 38 (D) weeks of BEV therapy shows progressively decreasing size of the contrast-enhancing lesion with improvement in swelling and mass effect. E: Six weeks after stopping BEV the image shows recurrence of the enhancing lesion. F: Twelve weeks after stopping BEV the image shows dramatic increase in enhancement. The patient died 20 weeks after stopping BEV therapy because of progressive increase in size of the tumor.